|Bid||44.74 x 1000|
|Ask||46.02 x 1000|
|Day's Range||45.44 - 46.65|
|52 Week Range||12.54 - 49.16|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||27.51|
|Forward Dividend & Yield||0.01 (0.02%)|
|Ex-Dividend Date||Jun. 14, 2021|
|1y Target Est||N/A|
Owens & Minor (OMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioNTech and Pfizer look for the vaccine to rake in sales of around $26 billion this year. BioNTech's shares are trading at a seeming bargain because investors aren't sure how much recurring revenue the company will be able to count on after 2022. If booster doses are needed going forward, BioNTech's future sales could be massive for a long time to come.